Both the FDA and the European Medicines Agency (EMA) have accepted applications to review ozanimod, an oral sphingosine 1-phosphate receptor modulator, for the treatment of relapsing forms of multiple ...
Credit: Getty Images. The FDA has accepted for review the New Drug Application (NDA) for ozanimod (Celgene), an investigational treatment for relapsing forms of multiple sclerosis (MS). The Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results